Abraxis BioScience successfully defends patent covering platform technology for nanoparticles of protein coated drugs in Opposition Proceeding
Clients Celgene Corporation
Jones Day successfully defended Abraxis Bioscience's patent covering its platform technology - Nab™ - for protein coated nanoparticles opposed by Teva Pharmaceutical Industries in January 2010. The Opposition Division of the European Patent Office in its hearing on November 17, 2011 decided to maintain the patent, which covers, amongst others, Abraxis' medicament Abraxane®, which is albumin-coated paclitaxel approved for treating metastatic breast cancer. Abraxis was acquired by Celgene Corporation in October 2010.